RxDoctor Payments Data

Benjamin Chouake, MD

Internal Medicine · Cliffside Park, NJNPI 1891804654

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.4% of the total across 11 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Medtronic accounts for 60.2% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2020 at $172 and has fallen 71.6% since, to $49 in 2025. That places this record below the midpoint for internal medicine clinicians in NJ, where the typical reported total is $332.

$350in general payments, 2019–2025

Across 11 payments — averaging $31.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$210
  • AbbVie$48
  • AstraZeneca$31
  • GSK$27
  • Johnson & Johnson$17
  • Amgen$16

What the payments were for

  • Food & beverage$33495%
  • Education$165%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic(2 entities)2$210
AbbVie3$48
AstraZeneca2$31
GSK2$27
Johnson & Johnson1$17
Amgen1$16

How this compares

$350 in reported general payments places this provider in the 50th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey →

Medicare billing

Part B allowed, 2024
$293,454
Medicare patients
768
Services billed
7,111

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban78$75,809
OzempicSemaglutide41$46,348
XareltoRivaroxaban24$32,666
JardianceEmpagliflozin14$18,445
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$8,383
LinzessLinaclotide11$7,845
SymbicortBudesonide/Formoterol Fumarate23$7,773
Rosuvastatin Calcium320$6,224
Fenofibrate32$5,788
NexiumEsomeprazole Magnesium14$5,784
Stiolto RespimatTiotropium Br/Olodaterol Hcl13$5,753
Lantus SolostarInsulin Glargine,hum.Rec.Anlog26$4,641
Atorvastatin Calcium406$4,373
ZetiaEzetimibe11$4,293
PaxlovidNirmatrelvir/Ritonavir47$4,072

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$17$32,66624 claims
AstraZenecaSymbicort, Nexium$31$13,55737 claims
GSKTrelegy Ellipta$27$8,38312 claims
AbbVieLinzess$48$7,84511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Cliffside Park

See the full list for New Jersey →

Where these figures come from

Is this you, or does something look wrong? →